ClinicalTrials.gg
CompletedNCT01545388Updated Aug 22, 2018Results posted

Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136)

A Phase 3 interventional study of Sitagliptin and Metformin in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2018-08-22.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
337
Allocation
Randomized
Ages
20 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.

Enrollment
62nd of 287
337 · median 100
Started
2012
with 22 others
Phase 3
72 of 293
1 open now
Registered
148th of 293
by date
Lead sponsor
16 of 293
Merck Sharp & Dohme LLC

Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 62nd largest by enrollment of the 287 interventional ones that give a count, is one of 23 that started in 2012, is one of 72 in phase 3, and was the 148th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 20 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies testing metformin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study will evaluate the effect of the addition of metformin once daily (q.d.) or twice daily (b.i.d.) to sitagliptin monotherapy in Japanese participants with Type 2 diabetes mellitus (T2DM) who have inadequate glycemic control with diet/exercise therapy and sitagliptin monotherapy. The primary hypotheses are that the addition of metformin 250 mg b.i.d. or metformin 500 mg q.d. is superior to the addition of placebo on the change from baseline in hemoglobin A1c (HbA1c) at 24 weeks and that the addition of metformin 500 mg q.d. is non-inferior to the addition of metformin 250 mg b.i.d. on the change from baseline in HbA1c at 24 weeks.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
20 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 Diabetes Mellitus (T2DM)
  • Currently being treated with diet/exercise and on stable dose of sitagliptin for ≥ 4 weeks, on any additional oral hypoglycemic agent (AHA) in the prior 8 weeks, and ≥ 6.0% and ≤ 9.0%; or
  • Currently being treated with diet/exercise and on stable dose of sitagliptin for ≥ 10 weeks, not on any additional oral AHA in the prior 8 weeks, and HbA1c ≥ 6.5% and \< 10.0%

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes mellitus,
  • Secondary diabetes mellitus, or
  • Gestational diabetes mellitus
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
337 participants (actual)

Study arms

  • Experimental
    Metformin 500 mg q.d.

    Participants will receive sitagliptin daily (continuing their pre-study dose), 2 metformin 250 mg tablets in the morning and 1 matching placebo tablet in the evening.

    Drug: Sitagliptin · Drug: Metformin · Drug: Placebo

  • Experimental
    Metformin 250 mg b.i.d.

    Participants will receive sitagliptin daily (continuing their pre-study dose), 1 metformin 250 mg tablet and 1 matching placebo tablet in the morning and 1 metformin 250 mg tablet in the evening.

    Drug: Sitagliptin · Drug: Metformin · Drug: Placebo

  • Placebo comparator
    Placebo

    Participants will receive sitagliptin daily (continuing their pre-study dose), 2 matching placebo tablets in the morning and 1 matching placebo tablet in the evening.

    Drug: Sitagliptin · Drug: Placebo

Interventions

  • Sitagliptin, orally, 50 or 100 mg tablet (continuation of the pre-study dose)

    Also known as: MK-0431/ONO-5435

  • Metformin, orally, 500 mg daily (single dose; two 250 mg tablets) for 24 weeks

  • Metformin, orally, 500 mg daily (divided dose; 250 mg tablet b.i.d.) for 24 weeks

  • DrugPlacebo

    Placebo to match metformin 250 mg tablets, orally, for 24 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c)

    Based on a constrained longitudinal data analysis (cLDA) model with terms for treatment, other prior antihyperglycemic agent (AHA) therapy status other than sitagliptin (yes/no), study drug regimen (just before meal/after meal), sitagliptin dosage (50 mg/100 mg), time and the interaction of time by treatment, time by other prior AHA therapy status, time by study drug regimen, time by sitagliptin dosage and study drug regimen by sitagliptin dosage, with a constraint that the mean baseline is the same for all treatment groups.

    Time frame: Baseline and Week 24

  2. Percentage of Participants Who Experienced at Least One Adverse Event

    Time frame: Up to 26 weeks

  3. Number of Participants Who Discontinued Study Drug Due to an Adverse Event

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG)

    Based on a cLDA model with terms for treatment, other prior AHA therapy status other than sitagliptin (yes/no), study drug regimen (just before meal/after meal), sitagliptin dosage (50 mg/100 mg), time and the interaction of time by treatment, time by other prior AHA therapy status, time by study drug regimen, time by sitagliptin dosage and study drug regimen by sitagliptin dosage, with a constraint that the mean baseline is the same for all treatment groups.

    Time frame: Baseline and Week 24

07

Results

Posted Mar 26, 2014

Participant flow

Participant flow — Overall Study
MilestoneMetformin 500 mg q.d.Metformin 250 mg b.i.d.Placebo
Started13813366
Completed13012258
Not completed8118
Withdrew: Adverse event241
Withdrew: Lack of efficacy325
Withdrew: Participant moved or relocated100
Withdrew: Withdrawal by subject142
Withdrew: Other110

Outcome measures

PrimaryChange From Baseline to Week 24 in Hemoglobin A1c (HbA1c)

Based on a constrained longitudinal data analysis (cLDA) model with terms for treatment, other prior antihyperglycemic agent (AHA) therapy status other than sitagliptin (yes/no), study drug regimen (just before meal/after meal), sitagliptin dosage (50 mg/100 mg), time and the interaction of time by treatment, time by other prior AHA therapy status, time by study drug regimen, time by sitagliptin dosage and study drug regimen by sitagliptin dosage, with a constraint that the mean baseline is the same for all treatment groups.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percent of glycosylated hemoglobin
Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c)
Percent of glycosylated hemoglobinMetformin 500 mg q.d.Metformin 250 mg b.i.d.Placebo
Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c)-0.434 (-0.553 to -0.315)-0.587 (-0.708 to -0.467)0.091 (-0.073 to 0.255)
Statistical analysis
  • Metformin 250 mg b.i.d. vs Placebo · cLDA · p = <0.001 · Difference in least squares means: -0.678 · 95% CI -0.868 to -0.489Based on a cLDA model with the terms listed above and a constraint that the mean baseline is the same for all treatment groups.
  • Metformin 500 mg q.d. vs Placebo · cLDA · p = <0.001 · Difference in least squares means: -0.525 · 95% CI -0.713 to -0.337Based on a cLDA model with the terms listed above and a constraint that the mean baseline is the same for all treatment groups.
  • Metformin 500 mg q.d. vs Metformin 250 mg b.i.d. · Difference in least squares means: 0.153 · 95% CI 0.000 to 0.306
SecondaryChange From Baseline to Week 24 in Fasting Plasma Glucose (FPG)

Based on a cLDA model with terms for treatment, other prior AHA therapy status other than sitagliptin (yes/no), study drug regimen (just before meal/after meal), sitagliptin dosage (50 mg/100 mg), time and the interaction of time by treatment, time by other prior AHA therapy status, time by study drug regimen, time by sitagliptin dosage and study drug regimen by sitagliptin dosage, with a constraint that the mean baseline is the same for all treatment groups.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG)
mg/dLMetformin 500 mg q.d.Metformin 250 mg b.i.d.Placebo
Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG)-9.02 (-13.74 to -4.30)-11.27 (-16.07 to -6.46)7.32 (0.86 to 13.79)
Statistical analysis
  • Metformin 250 mg b.i.d. vs Placebo · cLDA · p = <0.001 · Difference in least squares means: -18.59 · 95% CI -25.94 to -11.24Based on a cLDA model with the terms listed above and a constraint that the mean baseline is the same for all treatment groups.
  • Metformin 500 mg q.d. vs Placebo · cLDA · p = <0.001 · Difference in least squares means: -16.34 · 95% CI -23.62 to -9.06Based on a cLDA model with the terms listed above and a constraint that the mean baseline is the same for all treatment groups.
  • Metformin 500 mg q.d. vs Metformin 250 mg b.i.d. · Difference in least squares mean: 2.25 · 95% CI -3.63 to 8.14
PrimaryPercentage of Participants Who Experienced at Least One Adverse Event
Time frame:
Up to 26 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Who Experienced at Least One Adverse Event
Percentage of participantsMetformin 500 mg q.d.Metformin 250 mg b.i.d.Placebo
Percentage of Participants Who Experienced at Least One Adverse Event65.967.760.6
PrimaryNumber of Participants Who Discontinued Study Drug Due to an Adverse Event
Time frame:
Up to 24 weeks
Reported as:
Number · Participants
Number of Participants Who Discontinued Study Drug Due to an Adverse Event
ParticipantsMetformin 500 mg q.d.Metformin 250 mg b.i.d.Placebo
Number of Participants Who Discontinued Study Drug Due to an Adverse Event231

Adverse events

Collected over Up to 26 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Metformin 500 mg q.d.—4/138 (2.9%)29/138 (21%)
Metformin 250 mg b.i.d.—2/133 (1.5%)35/133 (26.3%)
Placebo—0/66 (0%)8/66 (12.1%)
Most frequent serious events
Most frequent serious events
EventMetformin 500 mg q.d.Metformin 250 mg b.i.d.Placebo
Anaphylactic reactionImmune system disorders0/1381/1330/66
Brain stem infarctionNervous system disorders0/1381/1330/66
GastroenteritisInfections and infestations1/1380/1330/66
Sternal fractureInjury, poisoning and procedural complications1/1380/1330/66
Cerebral infarctionNervous system disorders1/1380/1330/66
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders1/1380/1330/66
Most frequent other events
Most frequent other events
EventMetformin 500 mg q.d.Metformin 250 mg b.i.d.Placebo
NasopharyngitisInfections and infestations17/13828/1337/66
ConstipationGastrointestinal disorders8/1385/1330/66
Upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders8/1384/1331/66

Baseline characteristics

All participants as treated population defined as all randomized participants.

Age, Continuous
Age, Continuous(Years)Metformin 500 mg q.d.Metformin 250 mg b.i.d.PlaceboTotal
Mean59.46 ± 9.6159.65 ± 9.2260.05 ± 9.3059.65 ± 9.37
Sex: Female, Male
Sex: Female, Male(Participants)Metformin 500 mg q.d.Metformin 250 mg b.i.d.PlaceboTotal
Female524628126
Male868738211
Hemoglobin A1c (HbA1c)
Hemoglobin A1c (HbA1c)(Percent of glycosylated hemoglobin)Metformin 500 mg q.d.Metformin 250 mg b.i.d.PlaceboTotal
Mean7.60 ± 0.837.40 ± 0.687.53 ± 0.777.51 ± 0.76
Fasting plasma glucose (FPG)
Fasting plasma glucose (FPG)(mg/dL)Metformin 500 mg q.d.Metformin 250 mg b.i.d.PlaceboTotal
Mean158.58 ± 32.45148.98 ± 26.27154.27 ± 27.51153.95 ± 29.42
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2012 to primary completion in Mar 2013, 12 months.

Results were first posted in Mar 2014, 1 year after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 12 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2012
First posted
Mar 6, 2012
StartActual
Feb 23, 2012
Primary completionActual
Mar 12, 2013
CompletionActual
Mar 12, 2013
Results first posted
Mar 26, 2014
Last update
Aug 22, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01545388
Responsible party
Sponsor
First posted
Mar 6, 2012
Start date
Feb 23, 2012
Primary completion
Mar 12, 2013
Completion
Mar 12, 2013
Results posted
Mar 26, 2014
Last update
Aug 22, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion